Clinical Trial Update: The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study [Phase 2]

View source ↗

Summary

Phase 2 trial update for Deferasirox-AmBisome therapy in mucormycosis has completed with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucormycosis

Drugs mentioned

• Deferasirox-AmBisome

Snippet

Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Conditions: Mucormycosis | Phase 2 | Status: COMPLETED | Results posted: 2011-10-06